Category News

Hansoh Pharma HS-20089

Hansoh Pharma Presents Phase 2 Data on HS-20089 for Platinum-Resistant Ovarian Cancer at ESMO 2025

The investigational B7-H4–targeted antibody–drug conjugate HS-20089 demonstrates encouraging efficacy and manageable safety in patients with platinum-resistant ovarian cancer. Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announced positive phase 2 study findings of HS-20089, a B7-H4-targeted Antibody-drug Conjugate, in patients…

Read MoreHansoh Pharma Presents Phase 2 Data on HS-20089 for Platinum-Resistant Ovarian Cancer at ESMO 2025

Novartis Kisqali® 5-Year Data Show 28% Reduced Recurrence Risk in Early Breast Cancer

Novartis Kisqali® Shows Sustained Five-Year Benefit in Broad Early Breast Cancer Population Novartis today released results from the five-year analysis of the pivotal Phase III NATALEE trial, confirming the long-term efficacy of Kisqali® (ribociclib) in patients with high-risk stage II…

Read MoreNovartis Kisqali® 5-Year Data Show 28% Reduced Recurrence Risk in Early Breast Cancer
Agenus

Agenus Shows 39% Two-Year Survival with BOT/BAL in Refractory Solid Tumors at ESMO 2025

Agenus Reports Durable Two-Year Survival with BOT/BAL Combination Across Refractory Solid Tumors at ESMO 2025 Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its pioneering work in immuno-oncology, unveiled highly encouraging new clinical data from its novel combination therapy…

Read MoreAgenus Shows 39% Two-Year Survival with BOT/BAL in Refractory Solid Tumors at ESMO 2025

FDA Grants Revolution Medicines Priority Voucher for Daraxonrasib (RMC-6236)

Revolution Medicines Receives FDA Priority Voucher for Daraxonrasib (RMC-6236) Under Commissioner’s National Priority Voucher Pilot Program Revolution Medicines Receives FDA Priority Voucher for Daraxonrasib (RMC-6236) Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company pioneering the development of targeted therapies…

Read MoreFDA Grants Revolution Medicines Priority Voucher for Daraxonrasib (RMC-6236)

Taiho Pharma Licenses PI3Kα Inhibitor Risovalisib to Haihe Biopharma

Taiho Pharma and Haihe Biopharma Form Exclusive Japanese Partnership for PI3Kα Inhibitor Risovalisib Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Haihe Biopharma Co., Ltd. (“Haihe”) today announced the signing of an exclusive license agreement for the development, manufacturing, and commercialization of…

Read MoreTaiho Pharma Licenses PI3Kα Inhibitor Risovalisib to Haihe Biopharma